Therapeutic strategies for congenital myasthenic syndromes
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS...
Autors principals: | Lee, M, Beeson, D, Palace, J |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
Wiley
2018
|
Ítems similars
-
The congenital myasthenic syndromes.
per: Palace, J, et al.
Publicat: (2008) -
Congenital myasthenic syndromes.
per: Beeson, D, et al.
Publicat: (1997) -
Congenital myasthenic syndromes: an update.
per: Finlayson, S, et al.
Publicat: (2013) -
Congenital myasthenic syndromes and the neuromuscular junction.
per: Cruz, P, et al.
Publicat: (2014) -
The neuromuscular junction and wide heterogeneity of congenital myasthenic syndromes
per: Rodríguez Cruz, P, et al.
Publicat: (2018)